π¬ New drug shows promise against tough blood cancers
A first-in-class therapy targeting MYC showed strong activity against treatment-resistant blood cancers in a new preclinical study. Researchers at The University of Texas MD Anderson Cancer Center found that the drug GT19630 interrupts a cycle between MYC and GSPT1 in leukemia, lymphoma, and multiple myeloma. This was reported in the journal Blood on unspecified dates. Scientists struggled for decades to block MYC, which drives about 70% of human cancers. Future studies will determine if this strategy is safe and effective in human patients. π¬